Shots:

• The P-II (CITYSCAPE) trial evaluates tiragolumab + Tecentriq vs Tecentriq alone in a ratio (1:1) in 135 patients with PD-L1-positive LA, unresectable or metastatic NSCLC
• The results showed an improvement in PFS & OS in the ITT population after 2.5yrs. of median follow-up with m-PFS (5.6mos. vs 3.9mos.) & m-OS (23.2mos. vs 14.5mos.); 38% reduction in risk of disease worsening or death (PFS); improvement in ORR (38.8% vs 20.6%)
• In a predefined exploratory analysis in the PD-L1-high population, 71% reduction in risk of disease worsening or death; m-PFS (16.6mos. vs 4.1mos.); ORR (69% vs 24.1%), improvement in OS & median was not reached, was generally well-tolerated

 Ref: Businesswire | Image: Genentech